Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Pluristem Therapeutics (NASDAQ:PLUR) Inc. shares have reached a new 52-week high, touching $6.63 amidst a flurry of investor optimism, with an impressive 32.6% surge in the past week alone. According to InvestingPro data, the company maintains a healthy liquidity position with a current ratio of 5.04, though it currently appears overvalued based on Fair Value analysis. This milestone reflects a significant turnaround for the biotechnology firm, which specializes in developing novel therapeutics using placenta-based cell therapy. With a market capitalization of $50.52 million and remarkable revenue growth of 89.92%, Pluristem has shown promising development despite reporting negative EBITDA of -$21.47 million. The surge to a 52-week high underscores the market’s recognition of Pluristem’s advancements and the potential impact of its cell therapy products in the medical field. InvestingPro subscribers can access 8 additional key insights about Pluristem’s financial health and growth prospects.
In other recent news, Pluri Inc. has faced a significant setback as its subsidiary, Pluri Biotech Ltd., received a termination notice for a $4.2 million contract from the U.S. National Institute of Allergy and Infectious Diseases. This contract was intended to fund the development of Pluri’s PLX-R18 cell therapy for Hematopoietic Acute Radiation Syndrome. In more positive developments, Pluri has secured new patents in the U.S. and Israel for its immune cell expansion technologies, which are designed to produce Mucosal-Associated Invariant T cells for cancer treatment. Additionally, Pluri Inc. has announced its 2025 Annual Meeting of Shareholders will be held in May, marking a shift from the previous year’s schedule. The company has also entered into an exclusive agreement with Ukrainian biobank Hemafund to stockpile and potentially advance the PLX-R18 cell therapy in Ukraine. This partnership aims to address the urgent need for radiation countermeasures in the region and could generate significant revenue if successful. The collaboration with Hemafund will explore opportunities for clinical trials and seek funding for the development of PLX-R18 as an official radiation countermeasure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.